摘要
目的:观察瑞舒伐他汀对急性冠脉综合征(ACS)患者血浆组织因子(TF)、组织因子途径抑制物(TFPI)及血脂水平的影响。方法:选择2015-2017年60例ACS患者,其中急性心肌梗死(AMI)30例(AMI组),不稳定型心绞痛(UAP)患者30例(UAP组)。另选取正常对照组20例。将60例ACS患者随机分为瑞舒伐他汀组(32例)以及普通治疗组(28例)。用酶联免疫吸附法测定患者入院时及治疗2周后血浆TF、TFPI及血脂水平。结果:(1)AMI组、UAP组血浆TF、TFPI及低密度脂蛋白胆固醇(LDL-C)水平均明显高于对照组(均P<0.05),AMI组与UAP组组间差异无统计学意义。(2)治疗2周后,瑞舒伐他汀组血浆TF与血清LDL-C水平较治疗前明显降低(均P<0.01),TFPI水平较治疗前明显升高(P<0.05);普通治疗组治疗2周后上述指标与治疗前比较均无显著性差异。(3)瑞舒伐他汀组治疗2周后TF、TFPI水平的变化与血脂水平的变化均无相关性。结论:ACS患者血浆TF与TFPI水平明显升高。瑞舒伐他汀通过降低TF,升高TFPI水平,抑制血栓形成,且这种作用与调脂作用无关。
Objective：To observe effects of rosuvastatin on levels of plasma tissue factor（TF）,tissue factor pathway inhibitor（TFPI）and serum lipid in patients with acute coronay syndrome（ACS）.Method：We enrolled 60 patients with ACS including 30 with acute myocardial infarction（AMI）and 30 with unstable angina pectoris（UAP）.Other 20 patients without coronary heart disease served as control group.Sixty patients with ACS were randomly separated into rosuvastatin group（n=32）and routine group（n=28）.Levels of TF,TFPI and serum lipids were measured by enzyme-linked immunosorbent assay（ELISA）at admission and after 2 weeks of therapy.Result：（1） Levels of plasma TF,TFPI and LDL-C were significantly higher in AMI group and UAP group than those in control group（both P〈0.05）,but there was no statistical difference between the two ACS groups.（2） After 2 weeks of therapy,the level of plasma TF and the serum LDL-C were decreased while the level of plasma TFPI was significantly increased in rosuvastatin group（all P〈0.01）,but no significant difference was observed before and after treatment in routine group.（3） Changes of levels of TF or TFPI had no correlation with serum lipids in rosuvastatin group.Conclusion：Levels of plasma TF and TFPI are significantly higher in patients with ACS.Rosuvastatin inhibits the formation of thrombus by reducing the level of TF and increasing the level of TFPI,but this effect is unrelated to the regulation of blood lipids.
作者
金梅花
杨立波
薛莉
J IN Meihua;YANG Libo;XUE Li(Department of Cardiology,General Hospital of Ningxia Chin;Medical University,Yinchuan,75000)
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2018年第7期652-655,共4页
Journal of Clinical Cardiology
